How Can A Stage-Based Program To Determine HME Applicability Benefit Your API?

Poor active pharmaceutical ingredient (API) solubility remains one of the most persistent hurdles in oral dosage drug development. Converting crystalline molecules into amorphous solid dispersions (ASDs) offers a proven pathway to enhance bioavailability, and hot melt extrusion (HME) provides a continuous, solvent-free method to achieve this efficiently. However, committing extensive resources to HME without early feasibility analysis risks costly delays. Utilizing a stage-based evaluation program establishes clear decision gates based on rigorous scientific criteria—assessing thermal stability, polymer compatibility, and physical characteristics before advancing. This structured approach de-risks process development, accelerates the timeline to clinical manufacturing, and ensures a seamless transition into robust, high-yield commercial production.

Discover how early feasibility assessment can streamline your formulation strategy and maximize drug candidate viability.